Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0227)
Name
Oxidopamine
Synonyms
oxidopamine; 6-HYDROXYDOPAMINE; 1199-18-4; 5-(2-aminoethyl)benzene-1,2,4-triol; 2,4,5-Trihydroxyphenethylamine; 6-OHDA; Hydroxydopamine; Oxidopamina; Oxidopaminum; Topamine; 1,2,4-Benzenetriol, 5-(2-aminoethyl)-; 5-(2-Aminoethyl)-1,2,4-benzenetriol; 8HW4YBZ748; CHEMBL337702; CHEBI:78741; 6-Hydroxy Dopamine hydrobromide; MLS002207128; Oxidopamine [USAN:INN]; Oxidopaminum [INN-Latin]; Oxidopamina [INN-Spanish]; 6-HD; CCRIS 4342; SMR001306725; EINECS 214-842-3; BRN 2211011; UNII-8HW4YBZ748; 5-(2-aminoethyl)benzene-1,2,4-triol;hydrobromide; 6-hydroxy-dopamine; Spectrum_000309; Spectrum2_001018; Spectrum3_001753; Spectrum4_000462; OXIDOPAMINE [INN]; Oxidopamine (USAN/INN); OXIDOPAMINE [USAN]; SCHEMBL37507; BSPBio_003486; KBioGR_000904; KBioSS_000789; 4-13-00-02916 (Beilstein Handbook Reference); DivK1c_000362; SPBio_001175; cid_176170; DTXSID0036768; BDBM81264; KBio1_000362; KBio2_000789; KBio2_003357; KBio2_005925; KBio3_002706; NINDS_000362; KUC106765N; AKOS006230272; IDI1_000362; NCGC00167769-01; NCGC00167769-02; KSC-11-228-9; NCI60_001890; SBI-0051469.P003; D05294; AB00053512_09; Q780181; 5-(2-azanylethyl)benzene-1,2,4-triol;hydrobromide

    Click to Show/Hide
Structure
Formula
C8H11NO3
IUPAC Name
5-(2-aminoethyl)benzene-1,2,4-triol
Canonical SMILES
C1=C(C(=CC(=C1O)O)O)CCN
InChI
InChI=1S/C8H11NO3/c9-2-1-5-3-7(11)8(12)4-6(5)10/h3-4,10-12H,1-2,9H2
InChIKey
DIVDFFZHCJEHGG-UHFFFAOYSA-N
PubChem CID
4624
Full List of Ferroptosis Target Related to This Drug
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Parkinson disease ICD-11: 8A00
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
The AB strain of wild-type zebrafish (Danio rerio) was applied in this study. Zebrafish larvae at 4 dpf (days post-fertilization) were co-incubated with 250 uM 6-OHDA or 1.5 ug/mL nomifensine (Nomi, a dopamine transporter inhibitor) in 6-well plates at a density of 30 zebrafish embryos per group for 2 days and the medium was refreshed every day. The swimming total distance of each fish was recorded for 10 min and was analyzed by an automated video tracking system.

    Click to Show/Hide
Response regulation 6-hydroxydopamine (6-OHDA) treatment-induced ferroptosis in SH-SY5Y cells mainly by disturbing the protein expression of GPX4 and ACSL4. Collectively, the activation of the p62-Keap1-Nrf2 pathway prevents 6-OHDA-induced ferroptosis in SH-SY5Y cells, targeting this pathway in combination with a pharmacological inhibitor of ferroptosis can be a potential approach for parkinson's disease therapy.
Long-chain-fatty-acid--CoA ligase 4 (ACSL4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Driver
Responsed Disease Parkinson disease ICD-11: 8A00
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model SH-SY5Y cells Neuroblastoma Homo sapiens CVCL_0019
In Vivo Model
The AB strain of wild-type zebrafish (Danio rerio) was applied in this study. Zebrafish larvae at 4 dpf (days post-fertilization) were co-incubated with 250 uM 6-OHDA or 1.5 ug/mL nomifensine (Nomi, a dopamine transporter inhibitor) in 6-well plates at a density of 30 zebrafish embryos per group for 2 days and the medium was refreshed every day. The swimming total distance of each fish was recorded for 10 min and was analyzed by an automated video tracking system.

    Click to Show/Hide
Response regulation 6-hydroxydopamine (6-OHDA) treatment-induced ferroptosis in SH-SY5Y cells mainly by disturbing the protein expression of GPX4 and ACSL4. Collectively, the activation of the p62-Keap1-Nrf2 pathway prevents 6-OHDA-induced ferroptosis in SH-SY5Y cells, targeting this pathway in combination with a pharmacological inhibitor of ferroptosis can be a potential approach for parkinson's disease therapy.
References
Ref 1 Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells. Mol Neurobiol. 2020 Nov;57(11):4628-4641. doi: 10.1007/s12035-020-02049-3. Epub 2020 Aug 8.